News

Clinically meaningful increases in patient-reported outcomes were identified after 3 doses of SEL-212 and strengthened after 3 additional doses.

These data, presented at ACR 2024, demonstrate that response was maintained at 2 years among those with psoriatic arthritis who responded to bimekizumab at Week 16.

The Urate-Lowering Therapy to Acute Treatment Ratio (ULTrA) was linked to fewer gout-related hospital admissions.

Infusion reaction rates and serum level lowering were similar between 120-minute and 60-minute infusion cohorts in the phase 4 AGILE study.

Clowse discussed findings from the phase 3 PHOENYCS GO trial presented at the 2024 ACR Convergence.

Data from 2 studies presented at ACR 2024 demonstrate the potential of AI to improve access to quality rheumatological assessments.

Over half of patients treated with LEVI-04 had at least a 50% reduction in pain and over 25% had at least a 75% reduction.

The phase 3 PHOENYCS GO trial met its primary endpoint in achieving BICLA response at week 48 compared with placebo.

Over one-third of participants had had inadequate responses or intolerance to at least 3 prior b/tsDMARDs.

However, fewer patients experienced flares in the tofacitinib group than in the placebo group, among other positive findings.

Findings from the first and only controlled study for macrophage activation syndrome were presented at the ACR Convergence.

A-319 has been well-tolerated so far and dose-escalation is ongoing in the phase 1 trial.

People who used GC for over 2 years and 3 years had elevated risks of CVD and infection-related mortality, respectively, that never returned to pre-GC use levels.

IL-18 levels were consistently lower across participants with different SARDs, remission status, and COVID-19 disease characteristics.

This clinical quiz, our first in a series of 3, focuses on recommendations for specific vaccines from the 2022 ACR vaccination guidelines.

While an effective and promising strategy for chronic pain relief, more research on long-term cannabis usage is needed.

People with diabetes, kidney stones, damaged joints, high uric acids, and daily use of NSAID were more likely to develop CKD than others.

People that reported only some or none of their flares had almost twice the rate of gout flares in the last year than those reporting all of their flares.

Highest responders on DAS28 also had significantly greater decreases in 12-hydroxyeicosatetraenoic than low responders.

Combining interventions yielded no significant differences in outcomes, pain, or quality-of-life.

Veterans residing in rural areas were only 10% more likely to initiate biologic therapies than those residing in rural areas.

The pain reduction effects did not last long beyond the scope of the trial, underscoring the importance of continuing such exercises.

SGLT-2 inhibitors had more protective effects than GLP-1 receptor agonists or DPP-4 inhibitors in this population.

A new cohort study including over 6 million participants has found an increased likelihood of Behçet disease, alocpecia, bulbous pemphigoid and other disorders post-COVID infection.

The international phase 4 MOSAIC study is the first evaluating PsAMRIS and MRI-WIPE outcomes in patients with psoriatic arthritis.

Week 156 efficacy and safety data from the FINCH 4 study are consistent with that seen in FINCH 1, 2, and 3.

The rheumatology month in review emphasizes new data on secukinumab, gout clinical decision making, and addressing sleep issues in fibromyalgia.

SF-36v2 scores also improved by 12 points with semaglutide compared with 6.5 points with placebo.

Four of 5 participants with follow-up reaching 3 months have achieved SRI-4 disease responses.

Patients exposed to screening were also more likely to receive vaccinations and consult a cardiologist and/or a pneumologist.